Uncovering the role of extracellular condensates as triggers of neuroinflammation
Project Number1DP2NS142714-01
Former Number1DP2OD036927-01
Contact PI/Project LeaderBOEYNAEMS, STEVEN
Awardee OrganizationBAYLOR COLLEGE OF MEDICINE
Description
Abstract Text
PROJECT SUMMARY
Historically largely focused on the demise of neurons, a wealth of literature in the neurodegeneration field has
provided strong evidence for a critical role of neuroinflammation. It is now well established that both astro- and
microgliosis contribute to disease onset and/or progression. These glial cells can directly respond to the
aggregate/condensate pathology that characterizes these conditions and this has been suggested to underlie
their hyperinflammation. Yet, why this happens has been puzzling as humans never experienced selective
pressure to evolve the ability to detect age-related pathology. Why do glia respond to something they have never
been trained to respond to? The immune system did evolve detection systems for infection, and the evolutionary
arms race between humans and their pathogens has shaped a plethora of receptors and signaling cascades
that are involved in the sensing of and immediate response to infection. This is the innate immune system.
Recently, I unexpectedly discovered that some of these neuropathological proteins mimic the biophysical
behavior of innate immune signals. Antimicrobial peptides—mostly known for their killer activity towards
pathogens—also moonlight as pro-inflammatory signals. More specifically, these cationic peptides can promote
the immunogenicity of nucleic acids towards their Toll-like receptors, in a process that is dependent on the
electrostatic condensation of such peptides with the anionic nucleic acids. Condensing these immunogens
concentrates them, protects them from degradation, and drives their trafficking to their corresponding receptor—
hereby dramatically boosting the inflammatory response. Neuropathological proteins from many diseases
condense or aggregate with nucleic acids, suggesting that such potent immune triggers are commonly found in
the diseased brain. We show that the pathology associated with the most common genetic form of amyotrophic
lateral sclerosis and frontotemporal dementia indeed signals to the innate immune system via this condensation-
dependent mechanism. Thus, I propose the provocative idea that neuropathology in general must hijack such
ancient immune signaling cascades to trigger the immune system. This hypothesis provides and elegant
explanation of the decades-old question of the molecular origins of neuroinflammation.
In this proposal, my lab will set out to rigorously test this hypothesis using a multidisciplinary approach
that spans from biophysics to in vivo disease modeling. By leveraging our expertise in condensate biology,
building on preliminary data from our genetics- and proteomics-based approaches, and using in vitro and in vivo
models, we will uncover the biophysical rules and signaling cascades underlying this molecular mimicry.
Neuroinflammation is a key modifier of disease progression. If successful, we will identify promising new
candidates and compounds for therapeutic neuro-immunomodulation in these devastating diseases.
Public Health Relevance Statement
PROJECT NARRATIVE
Neuroinflammation is a major modifier of disease progression in neurodegenerative disease, yet we lack critical
insight into its molecular origins. Recently, we unexpectedly discovered that the pathological proteins found in
these conditions mimic the behavior of innate immune signals. Here, we propose to uncover the biophysical and
molecular rules that dictate this mimicry to help us better understand the etiology of neuroinflammation in disease
and aid us in devising new ways for therapeutic intervention.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Age related pathologiesAntigensBiologyBiophysicsBrain DiseasesDataDiseaseDisease ProgressionElectrostaticsEtiologyGeneticGliosisHumanImmuneImmune signalingImmune systemIn VitroInfectionInflammatoryInflammatory ResponseInnate Immune SystemInstinctLiteratureMolecularMolecular MimicryNerve DegenerationNeurodegenerative DisordersNeurogliaNeuroimmunomodulationNeuronsNucleic AcidsOnset of illnessPathologicPathologyPeptidesPhysical condensationProcessProteinsProteomicsRoleShapesSignal TransductionTestingTherapeuticTherapeutic InterventionToll-like receptorsTraininganti-microbial peptidearms racedetection platformdisease modelexperienceextracellularfrontotemporal lobar dementia amyotrophic lateral sclerosisimmunogenicityin vivoin vivo Modelinsightinterdisciplinary approachmimicryneuroinflammationneuropathologypathogenpressurereceptorresponsetrafficking
National Institute of Neurological Disorders and Stroke
CFDA Code
310
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
20-September-2024
Project End Date
31-August-2027
Budget Start Date
20-September-2024
Budget End Date
31-August-2027
Project Funding Information for 2024
Total Funding
$1,440,000
Direct Costs
$900,000
Indirect Costs
$540,000
Year
Funding IC
FY Total Cost by IC
2024
NIH Office of the Director
$1,440,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1DP2NS142714-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP2NS142714-01
Patents
No Patents information available for 1DP2NS142714-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP2NS142714-01
Clinical Studies
No Clinical Studies information available for 1DP2NS142714-01
News and More
Related News Releases
No news release information available for 1DP2NS142714-01
History
No Historical information available for 1DP2NS142714-01
Similar Projects
No Similar Projects information available for 1DP2NS142714-01